¹⁸F-FDG PET/CT total lesion glycolysis is associated with circulating tumor cell counts in patients with stage I to IIIA non-small cell lung cancer.

ABSTRACT:

Background

In non-small cell lung cancer (NSCLC), ¹⁸F-fluoro-2-deoxy-D-glucose (¹⁸F-FDG) uptake determined by PET and presence of circulating tumor cells (CTCs) in the peripheral blood independently predict outcomes. For ¹⁸F-FDG PET/CT staging interpretation, standardized uptake values (SUV_max/avg) are routinely used in clinical reporting. The goal was to investigate whether ¹⁸F-FDG uptake measured by SUV_max/avg, but also measures of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) (MTV × SUV_avg), are associated with CTCs.

Methods

Prospectively, 7.5 mL blood was drawn from NSCLC patients at the time of staging 18F-FDG PET/CT and from healthy control subjects. CTCs were identified by im

SUBMITTER: Avella DM 

PROVIDER: S-EPMC7354116 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature